Intraocular Pressure Following Intravitreal Injection of Triamcinolone Acetonide§

Ejaz A Ansari*, N Ali1
1 Maidstone and Tunbridge Wells NHS Trust, Department of Ophthalmology, Maidstone Hospital, Hermitage Lane, Maidstone, ME16 9QQ, UK

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 3058
Abstract HTML Views: 2084
PDF Downloads: 921
Total Views/Downloads: 6063
Unique Statistics:

Full-Text HTML Views: 1426
Abstract HTML Views: 1295
PDF Downloads: 657
Total Views/Downloads: 3378

Creative Commons License
© Ansari and Ali; Licensee Bentham Open

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

* Address correspondence to this author at the the Maidstone and Tunbridge Wells NHS Trust, Department of Ophthalmology, Maidstone Hospital, Hermitage Lane, Maidstone, ME16 9QQ, UK; Tel: 01622 226275; E-mail:
This work was accepted and presented as a poster presentation at EVER, Vilamoura, Portugal 4-6/10/06; Royal College of Ophthalmologists Annual Congress Meeting, Manchester, UK 24/05/06; and Association for Research and Vision in Ophthalmology, Florida, USA (ARVO) 03/05/06.



To investigate the intraocular pressure (IOP) response following intravitreal injection of triamcinolone acetonide.


This retrospective consecutive non-comparative case series study included 41 patients (52 eyes) (19 male, 22 female, mean age 64.1 ± 13.44; range 22 – 85 years) with progressive exudative ARMD (n = 10 eyes) or diffuse diabetic macular oedema (42 eyes), who received one or more intravitreal injection(s) of 4 mg triamcinolone acetonide.


IOP increased significantly (p<0.001) from 16.08 (±3.28) mm Hg (range 12-26 mm Hg) preoperatively to a mean maximum of 26.1 (±11.79) mmHg (range 15-80 mm Hg) postoperatively (p<0.001). An IOP rise to values higher than 21 mm Hg was observed in 28 (53.8%) eyes. Elevation of IOP occurred 7.5 weeks (±7.07) after the injection. All five patients (11.9%) with a family history of glaucoma developed an IOP rise above the mean maximum level. The post-injection rise of IOP was statistically independent of gender (p=0.37), but the presence of diabetes mellitus demonstrated a marked influence on the rate of a postoperative elevation of IOP (p=0.05).


The IOP response following IVTA was consistent with previous studies. A family history of glaucoma and a history of diabetes mellitus may predispose patients to a greater than average IOP rise following IVTA. Careful IOP assessment for at least 6 months post injection is recommended.